Previous 10 | Next 10 |
2023-07-13 12:35:00 ET Summary Will tough times continue for psychedelic stocks? Analyst Alex Carchidi shares his views on the sector and specific stocks like Compass Pathways, Atai and Cybin. Inevitability of big pharma entering the space. Listen below or on the g...
Leading psychiatrists and researchers examine common assumptions about the term “psychedelic-assisted psychotherapy” and the role of psychotherapy when evaluating psilocybin treatment. Authors highlight the need for clarity in terminology and definition to accurately assess the ...
Bipartisan congressional legislators are pleased with recent actions by the U.S. Food and Drug Administration (FDA) regarding psychedelic policy and research. Only a few days after the lawmakers filed a bill requesting that the agency craft measures to guide psychedelic research in the United Sta...
2023-07-07 10:07:00 ET Gainers: Castle Biosciences ( CSTL ) +43% . CareDx ( CDNA ) +20% . COMPASS Pathways ( CMPS ) +9% . TG Therapeutics ( TGTX ) +9% . KalVista Pharmaceuticals ( KALV ) +8% . Losers: PainReform ( P...
New code will facilitate reimbursement for psychedelic therapy in the US, if approved COMPASS Pathways to hold webinar on new code on Tuesday, July 11, 8:00 am EDT (1:00 pm BST) LONDON, July 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a ...
LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that the Company has entered into a term loan agreement with Hercules Capital, Inc....
2023-07-02 03:27:56 ET Summary Psilocybin is shown to be effective at treating a wide range of illnesses. COMP360 is in phase 3 clinical trials for treating treatment-resistant depression. No other psilocybin-oriented substance is in phase 3 trials at this time, and if it is a...
2023-07-01 10:04:00 ET While Compass Pathways ' (NASDAQ: CMPS) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by 458% to reach around $42.30 within the next 12 months. There's no doubt that the psychedelic therapy developer h...
The Colorado Convention Center recently hosted the latest iteration of Psychedelic Science, a massive psychedelic-themed event that attracted thousands of attendees from around the world. Psychedelic Science 2023 was the largest psychedelic conference ever held worldwide, bringing in nearly 12,...
2023-06-26 17:20:36 ET Gainers: Terns Pharmaceuticals ( NASDAQ: TERN ) +7% . Savara ( SVRA ) +5% . Nkarta ( NKTX ) +5% . COMPASS Pathways ( CMPS ) +3% . Matterport ( MTTR ) +2% . Losers: Adicet ( ACET ...
News, Short Squeeze, Breakout and More Instantly...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...